Article
Genetic predisposition to neuroleptic malignant syndrome : implications for antipsychotic therapy.
American journal of pharmacogenomics : genomics-related research in drug development and clinical practice - 1 Jan 2003
Kawanishi Chiaki
Abstract excerpt
The pathogenetic mechanism of neuroleptic malignant syndrome (NMS), a potentially lethal adverse effect of antipsychotics, is not well understood. In addition to acquired risk factors, clinical observations suggest a number of genetic factors predisposing patients to NMS. Recent findings in pharmacogenetics indicate that the genetic polymorphisms for drug-metabolizing enzymes, drug transporters, and possibly...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.